Northern Trust Corp Atara Biotherapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.44 - $1.22 $2,373 - $6,580	5,394 Added 0.64%	850,821 $587,000
Q4 2023 Feb 13, 2024	BUY	$0.23 - $1.74 $10,696 - $80,918	46,505 Added 5.82%	845,427 $431,000
Q3 2023 Nov 13, 2023	BUY	$1.41 - $2.31 $5,190 - $8,503	3,681 Added 0.46%	798,922 $1.18 Million
Q2 2023 Aug 11, 2023	SELL	$1.5 - $3.04 $122,434 - $248,133	-81,623 Reduced 9.31%	795,241 $1.28 Million
Q1 2023 May 15, 2023	SELL	$2.8 - $5.46 $11,306 - $22,047	-4,038 Reduced 0.46%	876,864 $2.54 Million
Q4 2022 Feb 13, 2023	BUY	$2.85 - $5.18 $72,979 - $132,644	25,607 Added 2.99%	880,902 $2.89 Million
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $36,223 - $110,958	-12,710 Reduced 1.46%	855,295 $3.23 Million
Q2 2022 Aug 12, 2022	BUY	$4.69 - $9.84 $169,088 - $354,761	36,053 Added 4.33%	868,005 $6.76 Million
Q1 2022 May 13, 2022	SELL	$8.44 - $16.89 $238,894 - $478,071	-28,305 Reduced 3.29%	831,952 $7.73 Million
Q4 2021 Feb 08, 2022	BUY	$14.7 - $19.89 $250,017 - $338,289	17,008 Added 2.02%	860,257 $13.6 Million
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $342,410 - $511,188	-28,558 Reduced 3.28%	843,249 $15.1 Million
Q2 2021 Aug 13, 2021	SELL	$12.89 - $16.58 $326,207 - $419,590	-25,307 Reduced 2.82%	871,807 $13.6 Million
Q1 2021 May 12, 2021	SELL	$14.0 - $20.72 $180,292 - $266,832	-12,878 Reduced 1.42%	897,114 $12.9 Million
Q4 2020 Feb 11, 2021	BUY	$12.67 - $26.23 $157,082 - $325,199	12,398 Added 1.38%	909,992 $17.9 Million
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $1.42 Million - $1.89 Million	118,914 Added 15.27%	897,594 $11.6 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $637,715 - $1.26 Million	84,690 Added 12.2%	778,680 $11.3 Million
Q1 2020 May 14, 2020	BUY	$5.69 - $17.78 $118,938 - $371,655	20,903 Added 3.11%	693,990 $5.91 Million
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $274,210 - $422,772	25,180 Added 3.89%	673,087 $11.1 Million
Q3 2019 Nov 13, 2019	BUY	$12.03 - $19.94 $1.6 Million - $2.65 Million	132,675 Added 25.75%	647,907 $9.15 Million
Q2 2019 Aug 13, 2019	SELL	$19.05 - $41.04 $196,957 - $424,312	-10,339 Reduced 1.97%	515,232 $10.4 Million
Q1 2019 May 13, 2019	BUY	$28.4 - $41.74 $106,840 - $157,025	3,762 Added 0.72%	525,571 $20.9 Million
Q4 2018 Feb 12, 2019	SELL	$30.9 - $42.97 $69,926 - $97,241	-2,263 Reduced 0.43%	521,809 $18.1 Million
Q3 2018 Nov 14, 2018	BUY	$35.05 - $43.5 $935,870 - $1.16 Million	26,701 Added 5.37%	524,072 $21.7 Million
Q2 2018 Sep 18, 2018	SELL	$35.15 - $51.45 $19,754 - $28,914	-562 Reduced 0.11%	497,371 $18.3 Million
Q2 2018 Aug 14, 2018	BUY	$35.15 - $51.45 $3.74 Million - $5.48 Million	106,497 Added 27.21%	497,933 $18.3 Million
Q1 2018 May 09, 2018	BUY	$18.0 - $48.35 $1.85 Million - $4.96 Million	102,663 Added 35.55%	391,436 $15.3 Million
Q4 2017 Feb 14, 2018	BUY	$13.2 - $18.1 $23,760 - $32,580	1,800 Added 0.63%	288,773 $5.23 Million
Q3 2017 Nov 13, 2017	BUY	$13.25 - $17.05 $3.8 Million - $4.89 Million	286,973	286,973 $4.75 Million

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account